Wikisage, the free encyclopedia of the second generation, is digital heritage
Naftidrofuryl: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
[[File:Naft 1-s2.0-S0048969716304491-fx1 lrg.jpg|miniature]] | |||
Naftidrofuryl is an antagonist of 5-HT2 receptor. | Naftidrofuryl is an antagonist of 5-HT2 receptor. | ||
==Links== | ==Links== | ||
[https://www.sciencedirect.com/science/article/abs/pii/S0248866319306599?via%3Dihub Naftidrofuryl dans l’artériopathie oblitérante des membres inférieurs : une revue systématique de la littératureNaftidrofuryl in arterial obstructive disease: A systematic revue of the literature] | [https://www.sciencedirect.com/science/article/abs/pii/S0248866319306599?via%3Dihub Naftidrofuryl dans l’artériopathie oblitérante des membres inférieurs : une revue systématique de la littératureNaftidrofuryl in arterial obstructive disease: A systematic revue of the literature] | ||
[https://www.sciencedirect.com/science/article/pii/S2210740119300531?via%3Dihub From tinnitus to acute hepatitis: Drug-induced injury caused by use of naftidrofuryl for one year] | [https://www.sciencedirect.com/science/article/pii/S2210740119300531?via%3Dihub From tinnitus to acute hepatitis: Drug-induced injury caused by use of naftidrofuryl for one year] | ||
[https://www.sciencedirect.com/science/article/pii/S0048969716304491?via%3Dihub Environmental risk analysis and prioritization of pharmaceuticals in a developing world context] | [https://www.sciencedirect.com/science/article/pii/S0048969716304491?via%3Dihub Environmental risk analysis and prioritization of pharmaceuticals in a developing world context] | ||
{{Wikidata|Q42867}} | {{Wikidata|Q42867}} | ||
Latest revision as of 16:00, 23 January 2020
Naftidrofuryl is an antagonist of 5-HT2 receptor.
Links
From tinnitus to acute hepatitis: Drug-induced injury caused by use of naftidrofuryl for one year
Environmental risk analysis and prioritization of pharmaceuticals in a developing world context
